Targeted Primary Prevention with Low-Dose Aspirin in Chronic Kidney Disease: The Predictive Role of Lipoprotein(a) Bio-Stratification- Dr Pradeep Kumar Meena

A 2025 analysis of the Chronic Renal Insufficiency Cohort (CRIC) published in JACC: Advances provides a practical solution to the long-standing primary prevention aspirin dilemma in Chronic Kidney Disease (CKD). While unstratified CKD patients show no overall benefit from aspirin, serum Lipoprotein(a) [Lp(a)] serves as a precise biological stratifier. Patients with Lp(a) ≥ 50 mg/dL achieve significant cardiorenal protection from low-dose aspirin, experiencing a 38% reduction in myocardial infarction (MI) risk and a 28% reduction in progression to End-Stage Renal Disease (ESRD). Crucially, this targeted approach introduces no statistically significant increase in major bleeding or stroke (1).

The Thrombo-Inflammatory Milieu of CKD

Chronic inflammation and oxidative stress drive a self-perpetuating cycle of kidney and cardiovascular (CV) damage in CKD. Biomarkers such as IL-6 and hsCRP directly correlate with more severe CKD, cardiovascular disease (CVD), and worse mortality outcomes (2).

Following this inflammatory cascade, endothelial dysfunction develops. Reduced nitric oxide bioavailability—driven by uremic toxins and asymmetric dimethylarginine (ADMA) accumulation—creates a highly prothrombotic and proinflammatory state. This environment accelerates atherosclerosis and medial calcification, a pathology distinct to CKD that is further fueled by secondary hyperparathyroidism in some cases. Vascular calcification subsequently stimulates macrophage activation and the release of inflammatory mediators, which impairs vascular reactivity and increases plaque vulnerability. Together, these complex interconnected mechanisms render CKD patients at an exceptionally high thrombogenic risk (3,4).

Lipoprotein(a): The Missing Link

While Lp(a) concentrations are at least 70% genetically determined, CKD stands out as one of the very few acquired conditions that actively elevates its circulating levels. As eGFR declines, serum Lp(a) levels rise due to the severely impaired renal clearance of particles carrying large apo(a) isoforms. Once elevated, Lp(a) exerts a destructive triple-threat mechanism (5,6):

Atherogenicity: Accelerates the oxidation of fatty streaks within the intimal layer of blood vessels (5).

Direct Renal Parenchymal Injury: Actively drives damage to the functional tissue of the kidneys by promoting intraluminal fibrosis (5).

Prothrombotic & Anti-Fibrinolytic Potential: Because of its structural homology with plasminogen, Lp(a) competitively blocks fibrinolysis, inhibiting the body's natural ability to break down blood clots (5,6).

Aspirin in Primary Prevention: Time for Reappraisal

Aspirin irreversibly inhibits cyclooxygenase-1, blocking thromboxane A₂ synthesis and subsequent platelet aggregation. Major guidelines, including the ACC/AHA, ESC, and ADA, suggest low-dose aspirin (75–162 mg) for individuals at high or very high CV risk, provided they do not present an elevated bleeding risk (7).

Meta-analyses of 14 randomized controlled trials (n = 167,587) show that while aspirin reduces major adverse cardiovascular events (MACE; RR 0.90), it significantly increases the risk of intracranial hemorrhage (RR 1.33) and extracranial bleeding (RR 1.67) across the general population. Historically, conventional trials excluded CKD patients. While low-dose aspirin has demonstrated no adverse renal effect (OR 0.97), this lack of robust, CKD-specific data has long limited its evidence-based utilization in clinical practice (8,9).

CRIC Analysis: Redefining Aspirin Utility in CKD

The 2025 CRIC analysis (n = 2,552, mean eGFR 47 mL/min/1.73 m², 27% with Lp(a) ≥ 50 mg/dL, 34% on aspirin at baseline) followed participants for a median of 15.7 years (1).

Among participants with Lp(a) ≥ 50 mg/dL, aspirin use conferred a 38% reduction in myocardial infarction risk (HR 0.62, 95% CI 0.42–0.91; P < 0.01), whereas no benefit was observed in those with Lp(a) < 50 mg/dL (HR 1.38). Furthermore, aspirin significantly reduced ESRD progression by 28% in the elevated Lp(a) group (HR 0.72), showing no notable effect in the lower Lp(a) cohort (HR 0.98) (1).

Figure 1: Lp(a)-stratified outcomes with aspirin use in CKD: findings from the CRIC analysis

Importantly, no statistically significant increase in major bleeding risk was observed in either Lp(a) stratum. These landmark findings establish Lp(a)-guided risk stratification as a powerful new paradigm for targeted aspirin allocation in CKD primary prevention (1).

Translating Evidence into Clinical Practice

 Key Takeaways

• CKD is a systemic vascular disorder characterized by a self-perpetuating thrombo-inflammatory milieu that substantially amplifies cardiovascular risk (10,11).

• Aspirin therapy, when precisely guided by an Lp(a) ≥ 50 mg/dL stratification, emerges as a highly effective targeted primary prevention strategy in CKD. It reduces MI risk by 38% and ESRD progression by 28% in the high Lp(a) subgroup without expanding major bleeding liabilities (7,8,9).

• Integrating eGFR, Lp(a), and inflammatory markers as core components of standard cardiovascular risk assessments enables the individualized cardiorenal risk reduction approach necessary for Indian CKD patients (1,9).

Abbreviations: ACC/AHA — American College of Cardiology/American Heart Association; ADA — American Diabetes Association; ADMA — asymmetric dimethylarginine; ASCVD — atherosclerotic cardiovascular disease; CI — confidence interval; CKD — chronic kidney disease; CRIC — Chronic Renal Insufficiency Cohort; CV — cardiovascular; eGFR — estimated glomerular filtration rate; ESC — European Society of Cardiology; ESRD — end-stage renal disease; HR — hazard ratio; hsCRP — high-sensitivity C-reactive protein; IL-6 — interleukin-6; Lp(a) — lipoprotein(a); MACE — major adverse cardiovascular events; MI — myocardial infarction; OR — odds ratio; RCT — randomized controlled trial; RR — risk ratio.